The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment landscape, outcome and quality of life in patients with pancreatic cancer: IKF642/PARAGON study.
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Ruediger Liersch
No Relationships to Disclose
 
Lars Scheuer
No Relationships to Disclose
 
Thomas Göhler
No Relationships to Disclose
 
Ulrich Kaiser
No Relationships to Disclose
 
Claudio Denzlinger
No Relationships to Disclose
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); PharmaMar (Inst); Roche (Inst)
 
Jan Wierecky
No Relationships to Disclose
 
Jorge Klagges
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Bianca Zäpf
No Relationships to Disclose
 
Ralf-Dieter Hofheinz
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Lilly; Medac; Merck Serono; MSD; Nordic Bioscience; Pierre Fabre; Roche; Sanofi; Servier
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Lilly; Merck Serono; MSD; Roche; Sanofi; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
Research Funding - German Cancer Aid (Inst); Medac (Inst); Sanofi (Inst)
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Frankfurter Institut für Klinische Krebsforschung IKF GmbH; Immutep
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma